Patents by Inventor Christopher John Arthur Finnis

Christopher John Arthur Finnis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11396670
    Abstract: The invention provides an improved host strain for production of desired protein.
    Type: Grant
    Filed: September 2, 2021
    Date of Patent: July 26, 2022
    Assignee: Albumedix Limited
    Inventors: Christopher John Arthur Finnis, Per Kristoffer Nordeide, Jennifer Mary McLaughlan
  • Publication number: 20220090159
    Abstract: The invention provides an improved host strain for production of desired protein.
    Type: Application
    Filed: September 2, 2021
    Publication date: March 24, 2022
    Inventors: Christopher John Arthur Finnis, Per Kristoffer Nordeide, Jennifer Mary McLaughlan
  • Patent number: 11130979
    Abstract: The invention provides an improved host strain for production of desired protein.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: September 28, 2021
    Assignee: Albumedix Ltd
    Inventors: Christopher John Arthur Finnis, Per Kristoffer Nordeide, Jennifer Mary McLaughlan
  • Publication number: 20210070839
    Abstract: The present invention relates to conjugation-competent albumins and albumin-related polypeptides, and their conjugates with at least one moiety, and to polynucleotides encoding them.
    Type: Application
    Filed: March 16, 2020
    Publication date: March 11, 2021
    Inventors: Karen Ann Delahay, Christopher John Arthur Finnis, Karl Michael Nicholls
  • Publication number: 20200392206
    Abstract: Based on the three-dimensional structure of albumin, the inventors have designed variant polypeptides (muteins) which have one or more cysteine residues with a free thiol group (hereinafter referred to as “thio-albumin”). The variant polypeptide may be conjugated through the sulphur atom of the cysteine residue to a conjugation partner such as a bioactive compound.
    Type: Application
    Filed: March 23, 2020
    Publication date: December 17, 2020
    Inventors: Christopher John Arthur Finnis, Joanna Mary Hay, Esben Peter Friis, Jason Cameron, Darrell Sleep
  • Publication number: 20200157155
    Abstract: The invention provides an improved host strain for production of desired protein.
    Type: Application
    Filed: May 17, 2019
    Publication date: May 21, 2020
    Applicant: Albumedix LTD.
    Inventors: Christopher John Arthur Finnis, Jennifer Mary Mclaughlan, Per Kristoffer Nordeide, Preethi Ramaiya
  • Patent number: 10633428
    Abstract: The present invention relates to conjugation-competent albumins and albumin-related polypeptides, and their conjugates with at least one moiety, and to polynucleotides encoding them.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: April 28, 2020
    Assignee: ALBUMEDIX LTD
    Inventors: Karen Ann Delahay, Christopher John Arthur Finnis, Karl Michael Nicholls
  • Publication number: 20200123584
    Abstract: The invention provides an improved host strain for production of desired protein.
    Type: Application
    Filed: June 20, 2018
    Publication date: April 23, 2020
    Inventors: Christopher John Arthur Finnis, Per Kristoffer Nordeide, Jennifer Mary McLaughlan
  • Publication number: 20180265568
    Abstract: The present invention relates to conjugation-competent albumins and albumin-related polypeptides, and their conjugates with at least one moiety, and to polynucleotides encoding them.
    Type: Application
    Filed: August 19, 2016
    Publication date: September 20, 2018
    Inventors: Karen Ann Delahay, Christopher John Arthur Finnis, Karl Michael Nicholls
  • Patent number: 10023618
    Abstract: The invention provides an improved host strain for production of desired protein.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: July 17, 2018
    Assignee: Albumedix A/S
    Inventors: Christopher John Arthur Finnis, Jennifer Mary Mclaughlan, Per Kristoffer Nordeide, Preethi Ramaiya
  • Publication number: 20180105818
    Abstract: The present disclosure relates to a method for producing heterologous protein including: (a) providing a host cell comprising a 2 ?m-family plasmid, the plasmid comprising a gene encoding a protein comprising the sequence of a chaperone protein and a gene encoding a heterologous protein; (b) culturing the host cell in a culture medium under conditions that allow the expression of the gene encoding the chaperone protein and the gene encoding a heterologous protein; (c) purifying the thus expressed heterologous protein from the cultured host cell or the culture medium.
    Type: Application
    Filed: July 19, 2017
    Publication date: April 19, 2018
    Applicant: Albumedix A/S
    Inventors: Darrell Sleep, Gillian Shuttleworth, Christopher John Arthur Finnis
  • Publication number: 20180022785
    Abstract: The invention provides an improved host strain for production of desired protein.
    Type: Application
    Filed: August 15, 2017
    Publication date: January 25, 2018
    Applicant: Albumedix A/S
    Inventors: Christopher John Arthur Finnis, Jennifer Mary Mclaughlan, Per Kristoffer Nordeide, Preethi Ramaiya
  • Publication number: 20180009856
    Abstract: The invention provides an improved host strain for production of desired protein.
    Type: Application
    Filed: May 12, 2017
    Publication date: January 11, 2018
    Applicant: Albumedix A/S
    Inventors: Christopher John Arthur Finnis, Jennifer Mary Mclaughlan, Per Kristoffer Nordeide, Preethi Ramaiya
  • Publication number: 20170081389
    Abstract: Based on the three-dimensional structure of albumin, the inventors have designed variant polypeptides (muteins) which have one or more cysteine residues with a free thiol group (hereinafter referred to as “thio-albumin”). The variant polypeptide may be conjugated through the sulphur atom of the cysteine residue to a conjugation partner such as a bioactive compound.
    Type: Application
    Filed: September 29, 2016
    Publication date: March 23, 2017
    Inventors: Christopher John Arthur Finnis, Joanna Mary Hay, Esben Peter Friis, Jason Cameron, Darrell Sleep
  • Patent number: 9493545
    Abstract: Based on the three-dimensional structure of albumin, the inventors have designed variant polypeptides (muteins) which have one or more cysteine residues with a free thiol group (hereinafter referred to as “thio-albumin”). The variant polypeptide may be conjugated through the sulphur atom of the cysteine residue to a conjugation partner such as a bioactive compound.
    Type: Grant
    Filed: February 11, 2010
    Date of Patent: November 15, 2016
    Assignee: Albumedix A/S
    Inventors: Christopher John Arthur Finnis, Joanna Mary Hay, Esben Peter Friis, Darrell Sleep
  • Publication number: 20160186192
    Abstract: The present invention provides a method for producing a desired protein (such as a desired heterologous protein) comprising: (a) providing a host cell comprising a first recombinant gene encoding a protein comprising the sequence of a first chaperone protein, a second recombinant gene encoding a protein comprising the sequence of a second chaperone protein and a third gene, such as a third recombinant gene, encoding a desired protein (such as a desired heterologous protein), wherein the first and second chaperones are different; and (b) culturing the host cell in a culture medium to obtain expression of the first, second and third genes.
    Type: Application
    Filed: January 26, 2015
    Publication date: June 30, 2016
    Inventors: Christopher John Arthur Finnis, Darrell Sleep, Gillian Shuttleworth
  • Patent number: 9057061
    Abstract: The present invention provides a method for producing a desired protein (such as a desired heterologous protein) comprising: (a) providing a host cell comprising a first recombinant gene encoding a protein comprising the sequence of a first chaperone protein, a second recombinant gene encoding a protein comprising the sequence of a second chaperone protein and a third gene, such as a third recombinant gene, encoding a desired protein (such as a desired heterologous protein), wherein the first and second chaperones are different; and (b) culturing the host cell in a culture medium to obtain expression of the first, second and third genes.
    Type: Grant
    Filed: December 23, 2005
    Date of Patent: June 16, 2015
    Assignee: NOVOZYMES BIOPHARMA DK A/S
    Inventors: Christopher John Arthur Finnis, Darrell Sleep, Gillian Shuttleworth
  • Patent number: 8969064
    Abstract: The present invention provides a method for producing a desired protein (such as a desired heterologous protein) comprising: (a) providing a host cell comprising a first recombinant gene encoding a protein comprising the sequence of a first chaperone protein, a second recombinant gene encoding a protein comprising the sequence of a second chaperone protein and a third gene, such as a third recombinant gene, encoding a desired protein (such as a desired heterologous protein), wherein the first and second chaperones are different; and (b) culturing the host cell in a culture medium to obtain expression of the first, second and third genes.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: March 3, 2015
    Assignee: Novozymes Biopharma DK A/S
    Inventors: Christopher John Arthur Finnis, Darrell Sleep, Gillian Shuttleworth
  • Publication number: 20140031294
    Abstract: The present invention provides a recombinant protein comprising the sequence of a transferrin mutant, wherein Ser415 is mutated to an amino acid which does not allow glycosylation at Asn413 and/or wherein Thr613 is mutated to an amino acid which does not allow glycosylation as Asn611. It also provides polynucleotides encoding the same and methods of making and using said recombinant protein.
    Type: Application
    Filed: July 29, 2013
    Publication date: January 30, 2014
    Applicant: Novozymes Biopharma DK A/S
    Inventors: Christopher John Arthur Finnis, Darrell Sleep, Joanna Hay
  • Publication number: 20130244277
    Abstract: The present invention provides a host cell suitable for enhanced production of a protein product of choice characterised in that the host cell is genetically modified to cause over-expression of two or more helper proteins selected from a DnaJ-like protein (such as JEM1), an Hsp70 family protein (such as LHS1) and SIL1, wherein at least one of the over-expressed two or more helper proteins is selected from JEM1, LHS1 and SIL1, and wherein the DnaJ-like protein is not SCJ1.
    Type: Application
    Filed: March 4, 2013
    Publication date: September 19, 2013
    Applicants: UNIVERSITY OF NOTTINGHAM, NOVOZYMES BIOPHARMA DK A/S
    Inventors: Thomas Payne, Darrell Sleep, Christopher John Arthur Finnis, Leslie Robert Evans